Related Experiment Video
Updated: Sep 16, 2025
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
Published on: October 21, 2017
Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized
Petrana Martinekova1,2, Mahmoud Obeidat1, Mihaela Topala1,3
1Centre for Translational Medicine, Semmelweis University, Budapest 1085, Hungary.
Context:
Vitamin D deficiency is highly prevalent in chronic liver disease. Although international societies recommend vitamin D supplementation in cases of proven deficiency, the impact of vitamin D on chronic liver disease remains uncertain.
Objective:
Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).
Data Sources:
We systematically searched PubMed, EMBASE and the Cochrane Library on July 2, 2024.
Data Extraction:
Our primary outcomes involved survival, controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and effects on changes in liver enzymes. Secondary outcomes included lipid profile and homeostasis model assessment of insulin resistance (HOMA-IR), among others. The pooled risk ratio (RR), mean difference (MD), and corresponding 95% CIs were calculated using the random-effects model.
Data Analysis:
Forty-six RCTs were included, comprising 4084 patients. When we compared the vitamin D group with the control, the RR for overall survival was 1.14 (95% CI, 0.85-1.54; 4 RCTs) at 6 months and 0.99 (95% CI, 0.83-1.17; 4 RCTs) at the 12-month follow-up. Vitamin D supplementation did not result in a lower CAP (MD, -23.50 dB/m; 95% CI, -81.72 to 34.72; 3 RCTs) and LSM (MD, -0.65 kPa; 95% CI, -1.98 to 0.68; 3 RCTs). A significant reduction in HOMA-IR was observed in the vitamin D group (MD, -0.31; 95% CI, -0.62 to -0.01; 15 RCTs). Alanine aminotransferase (ALT) (MD, -4.98 IU/L; 95% CI, -8.28 to -1.68; 24 RCTs), aspartate aminotransferase (AST) (MD, -3.33 IU/L; 95% CI, -6.25 to -0.40; 23 RCTs), gamma-glutamyl transferase (GGT) (MD, -5.14 IU/L; -6.40; -3.88; 11 RCTs), triglycerides (MD, -7.59 mg/dL; 95% CI, -15.09 to -0.81), and insulin (MD -0.79 μIU/L; 95% CI, -1.36 to -0.21) were significantly reduced in the patients with vitamin D supplementation.
Conclusion:
Our results showed significantly reduced ALT, AST, GGT, triglycerides, insulin, and HOMA-IR in the vitamin D-supplemented group; however, the effect was modest. In addition, there were no differences in survival, CAP, or LSM. Further RCTs with adequate power are warranted to clarify the results.
Systematic Review Registration:
PROSPERO registration No. CRD42022370312.
Related Concept Videos
01:23Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:22Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
01:28Chronic Kidney Disease III: Interprofessional Care
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...